Holen Sie sich die Stockscreener-App
16.26
0.31%
0.05
Handel nachbörslich:
16.26
Rxsight Inc Aktie (RXST) Neueste Nachrichten
JP Morgan downgrades RxSight on market, competitive pressures - Investing.com
JPMorgan Downgrades RxSight to Underweight From Overweight, Adjusts Price Target to $17 From $40 - MarketScreener
Deep Dive Into RxSight Stock: Analyst Perspectives (12 Ratings) - Benzinga
RxSight’s preliminary Q1 2025 revenue expected to increase 28% - Medical Buyer
American Express, Rxsight, Vertiv Holdings - TradingView
RxSight Inc (RXST) Q1 2025 Earnings Call Highlights: Strong Year-Over-Year Growth Amid Revised ... By GuruFocus - Investing.com Canada
RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) - Seeking Alpha
JPMorgan cuts RxSight stock rating, slashes price target to $17 By Investing.com - Investing.com South Africa
JPMorgan cuts RxSight stock rating, slashes price target to $17 - Investing.com India
RxSight stock plunges to 52-week low at $15.84 amid market challenges - Investing.com India
RxSight downgraded to Underweight from Overweight at JPMorgan - TipRanks
JPMorgan Double Downgrades RxSight Inc. (RXST) to Underweight - StreetInsider
Rxsight adjusts 2025 revenue guidance to $160M-$175M amid premium IOL market challenges - MSN
Earnings call transcript: RxSight Q1 2025 sees revenue growth, stock dips By Investing.com - Investing.com South Africa
RxSight Analyst Flags Growth Slowdown As Revised Outlook Misses Expectations - Benzinga
Biotech Shake-Up: Aldeyra Therapeutics & Others Feel The Heat - Finimize
RxSight Plunges 44% After Slashing 2025 Guidance; Bank of Americ - GuruFocus
BTIG cuts RxSight stock price target to $28 from $44 By Investing.com - Investing.com South Africa
RxSight stock tumbles on lowered 2025 guidance By Investing.com - Investing.com Canada
RxSight stock tumbles on lowered 2025 guidance - Investing.com
Earnings call transcript: RxSight Q1 2025 sees revenue growth, stock dips - Investing.com Canada
BTIG cuts RxSight stock price target to $28 from $44 - Investing.com
RxSight Q1 Revenue Miss, Guidance Cut Raise Growth Concerns, BofA Says - MarketScreener
RxSight Faces Market Challenges As Revenue Guidance Drops - Finimize
RxSight plunges after guidance cut; BofA downgrades - MSN
RxSight Inc. (RXST) PT Lowered to $28 at BTIG - StreetInsider
Stifel maintains RxSight stock hold, price target at $28 By Investing.com - Investing.com South Africa
BofA cuts RxSight stock rating, price target to $22 from $36 - Investing.com
Stifel maintains RxSight stock hold, price target at $28 - Investing.com
RxSight plunges after guidance cut - MSN
RxSight stock down after guidance cut (update) (RXST:NASDAQ) - Seeking Alpha
Sector Update: Health Care - MarketScreener
RxSight’s Growth Potential Amid Challenges: A Buy Recommendation by David Saxon - TipRanks
RxSight’s Long-Term Growth Potential Justifies Buy Rating Despite Short-Term Challenges - TipRanks
RxSight’s Undervaluation and Growth Potential Justify Buy Rating Despite Revenue Shortfall - TipRanks
RxSight double downgraded to Underperform at BofA after FY25 guidance cut - TipRanks
Needham maintains Buy on RxSight stock, price target at $43 By Investing.com - Investing.com South Africa
Needham maintains Buy on RxSight stock, price target at $43 - Investing.com India
BofA Securities Downgrades RxSight Inc. (RXST) to Underperform - StreetInsider
RxSight Warns On FY25 Revenue As Premium Cataract Market Faces Headwinds, Stock Plunges - Yahoo Finance
Needham Reiterates Buy Rating on RxSight Inc. (RXST) - StreetInsider
HighTower Advisors LLC Lowers Position in RxSight, Inc. (NASDAQ:RXST) - Defense World
RxSight Preliminary Q1 Revenue Increases; Lowers 2025 Revenue Guidance - MarketScreener
RxSight, Inc. Provides Revenue Guidance for the First Quarter 2025 - MarketScreener
RxSight sees Q1 revenue $37.9M, consensus $47.0M - TipRanks
RxSight Expects 28% Growth In Q1 Revenue; Cuts FY25 Revenue Outlook - Nasdaq
RxSight Cuts 2025 Revenue Target by $25M Despite Strong Lens Sales Growth - Stock Titan
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance - Bluefield Daily Telegraph
(RXST) Trading Report - news.stocktradersdaily.com
RxSight, Inc. (NASDAQ:RXST) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
BofA sees Bausch + Lomb IOL recall news as positive for RxSight - MSN
Midday Stock Roundup: Boot Barn, Beta Bionics down - Orange County Business Journal
RxSight Gains Competitive Edge with Market Shifts and Expansion Opportunities - TipRanks
RxSight, Inc. (NASDAQ:RXST) Shares Bought by Swiss National Bank - Defense World
RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Jefferies starts coverage on Rxsight with 'buy' on growth potential - TradingView
3.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):